PALI
Closed
Palisade Bio Inc
0.7151
+0.0350 (+5.15%)
Last Update: 01 Jul 2025 23:10:00
Yesterday: 0.6801
Day's Range: 0.7036 - 0.7329
Send
sign up or login to leave a comment!
When Written:
2.08
Palisade Bio Inc. is a biopharmaceutical company that focuses on developing novel treatments for chronic GI (gastrointestinal) diseases. The company's lead product candidate is called PA101, which is a combination of two naturally occurring compounds that are designed to treat patients with inflammatory bowel disease (IBD). Palisade Bio is also developing other products for the treatment of GI diseases, including PA102 for the treatment of ulcerative colitis and PA103 for the treatment of Crohn's disease.
The company was founded in 2016 and is headquartered in Princeton, New Jersey. Palisade Bio is publicly traded on the NASDAQ stock exchange under the ticker symbol "PALI." The company's management team includes experienced executives and scientists with expertise in drug development, clinical research, and commercialization.
Palisade Bio's mission is to improve the lives of patients suffering from chronic GI diseases by developing safe and effective treatments. The company's approach is based on a deep understanding of the underlying biology of these diseases and a commitment to developing innovative therapies that address their root causes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 2016 and is headquartered in Princeton, New Jersey. Palisade Bio is publicly traded on the NASDAQ stock exchange under the ticker symbol "PALI." The company's management team includes experienced executives and scientists with expertise in drug development, clinical research, and commercialization.
Palisade Bio's mission is to improve the lives of patients suffering from chronic GI diseases by developing safe and effective treatments. The company's approach is based on a deep understanding of the underlying biology of these diseases and a commitment to developing innovative therapies that address their root causes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








